Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Mesenchymal Stromal Cell Therapy by Orbsen Therapeutics for Autoimmune Hepatitis: Likelihood of Approval
Mesenchymal Stromal Cell Therapy is under clinical development by Orbsen Therapeutics and currently in Phase II for Autoimmune Hepatitis. According...
Mesenchymal Stromal Cell Therapy by Orbsen Therapeutics for Rheumatoid Arthritis: Likelihood of Approval
Mesenchymal Stromal Cell Therapy is under clinical development by Orbsen Therapeutics and currently in Phase II for Rheumatoid Arthritis. According...
Mesenchymal Stromal Cell Therapy by Orbsen Therapeutics for Lupus Nephritis: Likelihood of Approval
Mesenchymal Stromal Cell Therapy is under clinical development by Orbsen Therapeutics and currently in Phase II for Lupus Nephritis. According...
Mesenchymal Stromal Cell Therapy by Orbsen Therapeutics for Crohn's Disease (Regional Enteritis): Likelihood of Approval
Mesenchymal Stromal Cell Therapy is under clinical development by Orbsen Therapeutics and currently in Phase II for Crohn's Disease (Regional...
Mesenchymal Stromal Cell Therapy by Orbsen Therapeutics for Primary Sclerosing Cholangitis: Likelihood of Approval
Mesenchymal Stromal Cell Therapy is under clinical development by Orbsen Therapeutics and currently in Phase II for Primary Sclerosing Cholangitis....